RASSF1 and ovarian cancer: Decitabine proved more beneficial than 5-azacytidine for platinum-resistant ovarian cancer patients, producing a 35% objective response rate and a 10.2 month PFS that correlated with the degree of demethylation of the tumor suppressor genes MLH1, RASSF1A, HOXA10, and HOXA11, [65].